Investigating how tau pathology affects brain function in early Alzheimer's disease
Impact of locus coeruleus-derived tau pathology in a rodent model of early Alzheimer's disease
This study is looking at how changes in a protein called tau in a specific part of the brain might affect attention and thinking in early Alzheimer's disease, using a rodent model to find new ways to help treat the condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-10764294 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of tau protein abnormalities in the locus coeruleus, a brain region crucial for attention and cognition, in the context of early Alzheimer's disease. Using a rodent model, the researchers will introduce human tau into the locus coeruleus to mimic early Alzheimer's pathology. They will then examine how these tau changes affect neuron health, inflammation, and the potential spread of pathology to other brain areas. This approach aims to uncover new therapeutic targets for early intervention in Alzheimer's disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are older adults experiencing early symptoms of Alzheimer's disease, such as memory loss or cognitive decline.
Not a fit: Patients with advanced Alzheimer's disease or those without any cognitive impairment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies that target early Alzheimer's disease, potentially improving cognitive function and quality of life for patients.
How similar studies have performed: While research on tau pathology is ongoing, this specific approach targeting the locus coeruleus in early Alzheimer's disease is relatively novel and has not been extensively tested.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Weinshenker, David — Emory University
- Study coordinator: Weinshenker, David
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.